l General Information |
Product Name | Vonoprazan fumarate |
General description | Vonoprazan Fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase, controls gastric acid secretion. |
Synonym | (E)-but-2-enedioic acid; 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine; TAK-438 |
Purity | ≥99.0%(HPLC) | CAS Number | 1260141-27-2 |
Formula | C21H20FN3O6S | Molecular Weight | 461.46 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Very slightly soluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Vonoprazan Fumarate is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase, controls gastric acid secretion. |
Application | Vonoprazan has been used in trials studying the treatment of Erosive Esophagitis. |
l Packaging & Storage |
Packaging | 25mg; 250mg; 1g |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
